{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:31:45Z","timestamp":1777926705963,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim of the present study is investigating the incidence of bradycardia in COVID-19 patients treated with Remdesivir.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This prospective longitudinal study was conducted in a tertiary center on COVID-19 patients for Remdesivir therapy. The objectives were to investigate the incidence of sinus bradycardia, and also the association between their demographics, underlying diseases, and the disease severity with developing bradycardia in COVID-19 patients treated with Remdesivir.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of 177 patients, 44% were male. The mean (\u00b1standard deviation) age of patients was 49.79 \u00b1 15.16\u00a0years old. Also, 33% were hospitalized due to more severe symptoms. Oxygen support was required for all hospitalized subjects. A total of 40% of the patients had comorbidities, with the most common comorbidity being hypertension. The overall incidence of bradycardia (heart rate&amp;lt;60\u00a0bpm) in patients receiving Remdesivir was 27%, of whom 70% had extreme bradycardia (heart rate &amp;lt;50\u00a0bpm). There was also a statistically significant reduction in heart rate after five doses of Remdesivir compared to the baseline heart rates. In the multivariable model, none of the covariates including age above 60\u00a0years, female sex, CRP&amp;gt;50\u00a0mg\/L, O2 saturation&amp;lt;90%, underlying cardiovascular disease, hypertension and diabetes mellitus, and beta-blockers were associated with Remdesivir-induced bradycardia. No association was found between the COVID-19 severity indicators and bradycardia.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> As sinus bradycardia is a prevalent adverse cardiac effect of Remdesivir, it is recommended that all COVID-19 patients receiving Remdesivir, be evaluated for heart rate based on examination; and in the case of bradyarrhythmia, cardiac monitoring should be performed during administration to prevent adverse drug reactions.<\/jats:p>","DOI":"10.3389\/fphar.2022.1107198","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T05:31:52Z","timestamp":1673933512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study"],"prefix":"10.3389","volume":"13","author":[{"given":"Maryam","family":"Hajimoradi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Sharif Kashani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Dastan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Aghdasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atefeh","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Naghashzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arezoo","family":"Mohamadifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Sadegh","family":"Keshmiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Noorali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somayeh","family":"Lookzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloufar","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Amin","family":"Siri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadali","family":"Tavasolpanahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Abdolmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Shafaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra Sadat","family":"Rouhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Shafaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"B44","first-page":"122","article-title":"Clinical manifestations of patients with coronavirus disease 2019 (COVID-19) in a referral center in Iran","volume":"19","author":"Baghaei","year":"2020","journal-title":"Tanaffos"},{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/jcdd8020018","article-title":"Sinus bradycardia associated with remdesivir treatment in COVID-19: A case report and literature review","volume":"8","author":"Barkas","year":"2021","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1542-474x.1997.tb00325.x","article-title":"AN analysis of the time-relations of electrocardiograms","volume":"2","author":"Bazett","year":"1997","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1002\/jmv.27177","article-title":"Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study","volume":"93","author":"Bistrovic","year":"2021","journal-title":"J. Med. virology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/postgradmedj-2021-141079","article-title":"Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: A retrospective cohort study on 473 patients from a tertiary centre","volume":"98","author":"Bistrovic","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijid.2021.09.036","article-title":"Safety and heart rate changes in Covid-19 patients treated with Remdesivir","volume":"112","author":"Brunetti","year":"2021","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.gendis.2020.03.008","article-title":"The clinical and immunological features of pediatric COVID-19 patients in China","volume":"7","author":"Chen","year":"2020","journal-title":"Genes. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e245289","DOI":"10.1136\/bcr-2021-245289","article-title":"Remdesivir-associated bradycardia","volume":"14","author":"Ching","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104955","DOI":"10.1016\/j.antiviral.2020.104955","article-title":"Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes","volume":"184","author":"Choi","year":"2020","journal-title":"Antivir. Res."},{"key":"B10","volume-title":"(COVID-19) treatment guidelines","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E612","DOI":"10.1503\/cmaj.210300","article-title":"Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man","volume":"193","author":"Day","year":"2021","journal-title":"C Can. Med. Assoc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajem.2022.03.007","article-title":"Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support","volume":"55","author":"Drumheller","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.cegh.2020.100694","article-title":"Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives","volume":"10","author":"Ganesh","year":"2021","journal-title":"Clin. Epidemiol. Glob. Heal"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in patients with severe covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.jaccas.2020.08.025","article-title":"Marked sinus bradycardia associated with remdesivir in COVID-19: A case and literature review","volume":"2","author":"Gubitosa","year":"2020","journal-title":"JACC. Case Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e11132","DOI":"10.7759\/cureus.11132","article-title":"Cardiac adverse events with remdesivir in COVID-19 infection","volume":"12","author":"Gupta","year":"2020","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e14182","DOI":"10.1111\/ijcp.14182","article-title":"Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey","volume":"75","author":"Haghjoo","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13054-020-02933-3","article-title":"Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia","volume":"24","author":"Hu","year":"2020","journal-title":"Crit. care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.hrcr.2021.05.004","article-title":"Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease","volume":"7","author":"Jacinto","year":"2021","journal-title":"Hear. case Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/cts.13168","article-title":"Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database","volume":"15","author":"Jung","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00228-020-03008-6","article-title":"Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19","volume":"77","author":"Kow","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/clc.23622","article-title":"A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis","volume":"44","author":"Kumar","year":"2021","journal-title":"Clin. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/clc.23700","article-title":"Remdesivir therapy associated with Bradycardia in SARS-CoV2","volume":"44","author":"Kumar","year":"2021","journal-title":"Clin. Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cmi.2021.12.017","article-title":"Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients","volume":"28","author":"Lucijanic","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cts.12882","article-title":"Risk assessment of drug-induced long QT syndrome for some COVID-19 repurposed drugs","volume":"14","author":"Michaud","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.5812\/ijpr.123947","article-title":"National research institute of tuberculosis and lung disease (NRITLD) protocol for the treatment of patients with COVID-19","volume":"21","author":"Mirenayat","year":"2022","journal-title":"Iran. J. Pharm. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","article-title":"Potential cardiotoxic effects of remdesivir on cardiovascular system: A literature review","volume":"22","author":"Nabati","year":"2022","journal-title":"Cardiovasc Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.cmi.2021.04.013","article-title":"Prevalence and clinical significance of relative bradycardia at hospital admission in patients with coronavirus disease 2019 (COVID-19)","volume":"27","author":"Oliva","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jinf.2021.05.025","article-title":"Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)","volume":"83","author":"Pallotto","year":"2021","journal-title":"J. Infect."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/jmv.26898","article-title":"Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19)","volume":"93","author":"Pallotto","year":"2021","journal-title":"J. Med. virology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/jac\/dkaa321","article-title":"Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU","volume":"75","author":"Pasquini","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B42","first-page":"192","article-title":"NRITLD protocol for the management of outpatient cases of COVID-19","volume":"20","author":"Rezaei","year":"2021","journal-title":"TANAFFOS (Respiration)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"582348","DOI":"10.3389\/fphar.2020.582348","article-title":"Effect of triple combination therapy with lopinavir-ritonavir, Azithromycin, and hydroxychloroquine on QT interval and arrhythmic risk in hospitalized COVID-19 patients","volume":"11","author":"Russo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00431-021-03940-4","article-title":"Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection","volume":"180","author":"Sanchez-Codez","year":"2021","journal-title":"Eur. J. Pediatr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"572870","DOI":"10.3389\/fphar.2020.572870","article-title":"Potential therapeutic options for COVID-19: Current status, challenges, and future perspectives","volume":"11","author":"Sarkar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"ytab200","DOI":"10.1093\/ehjcr\/ytab200","article-title":"Complete heart block associated with remdesivir in COVID-19: A case report","volume":"5","author":"Selvaraj","year":"2021","journal-title":"Eur. heart J. Case Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): A new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mehy.2018.07.014","article-title":"Proposed mechanisms of relative bradycardia","volume":"119","author":"Ye","year":"2018","journal-title":"Med. Hypotheses"},{"key":"B41","doi-asserted-by":"publisher","first-page":"645651","DOI":"10.3389\/fmed.2021.645651","article-title":"Spectrum and clinical characteristics of symptomatic and asymptomatic coronavirus disease 2019 (COVID-19) with and without pneumonia","volume":"8","author":"Zeng","year":"2021","journal-title":"Front. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1107198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T17:10:12Z","timestamp":1673975412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1107198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":44,"alternative-id":["10.3389\/fphar.2022.1107198"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1107198","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"article-number":"1107198"}}